0001610717-23-000233.txt : 20230818
0001610717-23-000233.hdr.sgml : 20230818
20230818183359
ACCESSION NUMBER: 0001610717-23-000233
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230816
FILED AS OF DATE: 20230818
DATE AS OF CHANGE: 20230818
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stone Paul A.
CENTRAL INDEX KEY: 0001777511
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38915
FILM NUMBER: 231186946
MAIL ADDRESS:
STREET 1: C/O IDEAYA BIOSCIENCES, INC.
STREET 2: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc.
CENTRAL INDEX KEY: 0001676725
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474268251
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-6209
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Ideaya Biosciences, Inc.
DATE OF NAME CHANGE: 20160609
4
1
form4.xml
X0508
4
2023-08-16
0001676725
IDEAYA Biosciences, Inc.
IDYA
0001777511
Stone Paul A.
C/O IDEAYA BIOSCIENCES, INC.
7000 SHORELINE COURT, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
true
Chief Financial Officer
true
Common Stock
2023-08-16
4
S
0
100
26.45
D
19203
D
Common Stock
2023-08-16
4
S
0
100
26.4
D
19103
D
Common Stock
2023-08-18
4
S
0
3822
26.3789
D
15281
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.
This transaction was executed in multiple trades in prices ranging from $26.37 to $26.415, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
/s/ Jason Throne, as Attorney-in-Fact for Paul A. Stone
2023-08-18